Medline ® Abstract for Reference 6
of 'Intermediate- and long-term mechanical circulatory support'
Seventh INTERMACS annual report: 15,000 patients and counting.
Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB
J Heart Lung Transplant. 2015;34(12):1495. Epub 2015 Oct 8.
The seventh annual report of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) summarizes the first 9 years of patient enrollment. The Registry includes>15,000 patients from 158 participating hospitals. Trends in device strategy, patient profile at implant and survival are presented. Risk factors for mortality with continuous-flow pumps are updated, and the major causes/modes of death are presented. The adverse event burden is compared between eras, and health-related quality of life is reviewed. A detailed analysis of outcomes after mechanical circulatory support for ambulatory heart failure is presented. Recent summary data from PediMACS and MedaMACS is included. With the current continuous-flow devices, survival at 1 and 2 years is 80% and 70%, respectively.
Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: email@example.com.